13F Portfolios

Exome Asset Management LLC — ENLIVEN THERAPEUTICS INC ELVN: Quarterly 13F Position History

Exome Asset Management LLC has reported ENLIVEN THERAPEUTICS INC (ELVN) on 9 13F-HR filings in Pactolio's tracked window, first appearing in Q1 2024. As of Q1 2026, the position is sized at 220,091 shares ($8.6M market value, 5.08% of the equity book). Quarter-over-quarter share count change: 2,217 (-1.0%) .

Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 9 quarter s

Quarter Shares QoQ Share Change Share Change (%) Market Value Weight Implied Price
Q1 2026 220,091 2,217 -1.0% $8.6M 5.08% $39.20
Q4 2025 222,308 +222,308 $3.4M 1.69% $15.40
Q3 2025 0 0 $0 0.00%
Q2 2025 0 0 $0 0.00%
Q1 2025 0 0 $0 0.00%
Q4 2024 0 0 $0 0.00%
Q3 2024 0 0 $0 0.00%
Q2 2024 0 57,635 -100.0% $0 0.00%
Q1 2024 57,635 $1.0M 0.87% $17.59

Methodology & FAQ

How This Position History Is Sourced

Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.

When did Exome Asset Management LLC first disclose a ELVN position in 13F-HR filings?

Exome Asset Management LLC first reported ENLIVEN THERAPEUTICS INC (ELVN) on its 13F-HR filing for the period ending 2024-03-31 (Q1 2024). The position has appeared on 9 reported quarters within Pactolio's tracked window.

What was Exome Asset Management LLC's most recent quarter-over-quarter share-count change in ELVN?

Between Q4 2025 and Q1 2026, Exome Asset Management LLC reduced its ELVN position by 2,217 shares (-1.0%), leaving 220,091 shares at a market value of $8.6M.

Does the implied price-per-share represent Exome Asset Management LLC's cost basis in ELVN?

No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.